Treatment patterns, outcomes, and resource utilization of patients with metastatic melanoma in the U.K.: the MELODY study


  • Funding sources This work was supported by Bristol-Myers Squibb. Representatives from Bristol-Myers Squibb were involved in the study design; in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication and have been listed as authors of this manuscript. Editorial and writing assistance was provided by StemScientific, funded by Bristol-Myers Squibb. None of the authors received financial compensation for authoring the manuscript.
  • Conflicts of interest P.L. has acted as a consultant/advisor to Bristol-Myers Squibb, Roche, Novartis, Celgene and GSK, and has also received travel support from Bristol-Myers Squibb and Roche. M.M. has received travel support from and acted as a consultant/advisor to Bristol-Myers Squibb. R.O. has acted as a consultant/advisor to Bristol-Myers Squibb. At the time of writing, U.B. and Q.W. were employees of Bristol-Myers Squibb. Q.W. is currently at GlaxoSmithKline, Stockley Park, Uxbridge, U.K. L. P. is currently at Novo Nordisk, Copenhagen, Denmark.



Advanced melanoma is an aggressive disease with a poor prognosis. Approved therapy is limited in the U.K. and, until recently, no treatment had improved survival over best supportive care. A deeper understanding of current clinical practice will help new agents find a place in future treatment pathways.


To document U.K. clinical practice for the treatment of patients with unresectable stage III/IV (advanced) melanoma.


MELODY (melanoma treatment patterns and outcomes among patients with unresectable stage III/IV disease: a retrospective longitudinal survey) compiled registries of consecutive patients with malignant melanoma (any stage) between 1 July 2005 and 30 June 2006 from France, Italy and the U.K. Patients with advanced melanoma and ≥ 2 months of follow-up were eligible for analysis.


There were 220 eligible patients identified in the U.K., of whom 117 (53·2%) received systemic therapy outside of clinical trials. Over half of these patients received dacarbazine as first- or second-line therapy. Healthcare-resource utilization was extensive and patients had short survival times: 1- and 2-year survival rates after first-line systemic treatment were 45·5% [95% confidence interval (CI) 37·1–53·6] and 24·7% (95% CI 17·7–32·3), respectively.


Systemic and palliative treatments used to manage advanced melanoma in the U.K. are associated with considerable healthcare resource utilization and poor short-term survival.